The Penn Colton Center has launched two new Centers of Excellence — HIT-AI, focused on AI-driven drug repurposing, and CREATE, pioneering mRNA therapies — to accelerate next-generation autoimmune diagnostics and treatments.
A Colton-supported NYU Langone study has engineered a bispecific antibody that precisely silences harmful T cell activity — showing promise across mouse models of type 1 diabetes, hepatitis, and multiple sclerosis.
A Colton-supported Yale study published in Nature has shown for the first time that T cells live in the healthy brain, traveling there from the gut via a newly discovered gut-fat-brain axis.
The 2025 Penn Colton Center Symposium convened 150+ experts to explore breakthroughs in immune health and spotlight Penn's leadership, future headquarters, and innovations in autoimmunity research and precision medicine.
A Colton-supported Yale study published in Science Immunology shows that skin injury can trigger food allergies via a skin-gut immune connection — offering a new explanation for the link between eczema and food allergy.
A Colton-supported NYU study published in Science Translational Medicine has identified impaired regulatory T cells as a key driver of Sjögren's disease — and found a promising existing drug as a potential therapy.
Tel Aviv University's Colton Center has awarded nine interdisciplinary research grants in 2024, funding projects that explore autoimmune disease from organ-on-a-chip platforms to the role of stress and psychological factors in disease flare-ups.
Penn Medicine's Colton Center is leading a new wave of precision immunotherapy for autoimmune disease — from CAAR T cell therapy for pemphigus to immune profiling tools that could one day cure these conditions.
Yale's Colton Center for Autoimmunity has awarded $750,000 to seven faculty-led projects advancing research into autoimmune and allergic diseases, with funding, mentorship, and commercialization support.
NYU Langone researchers have linked lupus flare-ups to blooms of a specific gut bacterium, opening a potential path to probiotic and dietary treatments less toxic than current immunosuppressive therapies.
